Connect Biopharma Announced CBP-201 Atopic Dermatitis China Pivotal Study Met Primary And Secondary Endpoints
Author: Charles Gross | March 18, 2023 01:55pm
Connect Biopharma Holdings Limited (NASDAQ:CNTB
) announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16. The study met primary and secondary endpoints with mostly mild-to-moderate adverse effects reported. The data were presented as a late-breaking oral presentation today at the American Academy of Dermatology Annual Meeting, taking place in New Orleans, March 17-21.
Posted In: CNTB